Neurolixis

???????????????????? ?????????? ?????????? ???????? ?????????????? ?????? ?????????????????????? ???? ??????-?????? ?????? ?????????????????? ???? ???????? ???????????????? New data?from researchers at the?Universidade do Minho, Portugal, and from the University of Bristol, UK, show that???????-??????, a selective serotonin 5-HT1A receptor ‘biased agonist’ that targets specific brain regions, could bring much-needed hope to Rett syndrome patients and their carers. The study, supported by the International Rett Syndrome Foundation and published in the peer-reviewed journal??????????????????????? ?????? ??????????????????????????????, examined the effects of?NLX-101 in mice that lack genetic expression of MeCP2 (methyl CpG binding protein 2), thus?mimicking human Rett syndrome. The results suggest that NLX-101 can attenuate the damaging respiratory impairment and cognitive deficits seen in individuals with Rett syndrome.? Rett syndrome is characterized by severe neurophysiological, respiratory and cognitive impairment, and affects approximately 15 000 patients in the US and a similar number in Europe. NLX-101 has ‘Orphan Drug’ designation and has begun Phase 1 human study. The present data support its further development for treatment of Rett syndrome and related clinical indications. ?? Read the full publication (Open Access): https://lnkd.in/gAnP2WM3 ?? About Rett syndrome: https://lnkd.in/djT5kam ? #RettSyndrome #Biopharmaceuticals #Innovation #DrugDevelopment #Serotonin #Autism #RareDisease

??????-?????? ???????????????? ?????????? ?????????????? ???? ??????????????????’?? ?????????????? ?????????????????? Neurolixis has published the groundbreaking findings of its proof-of-concept clinical trial of NLX-112 (befiradol), a first-in-class selective serotonin 5-HT1A receptor agonist, in Parkinson’s disease. The Phase 2A study, featured in the prestigious journal,????????????????? ??????????????????, found that NLX-112 elicited dual efficacy in reducing levodopa-induced dyskinesia (LID) and also improving motor function in study participants. Supported by The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK, the trial met its primary endpoint of safety and tolerability, while significantly reducing LID and demonstrating anti-parkinsonian effects. Neurolixis is planning the next steps in the clinical development program to advance NLX-112 toward regulatory approval for treatment of movement disorders. ? ?? Full publication (Open Access): https://lnkd.in/exM_yuxq ?? About Parkinson’s disease: https://lnkd.in/gHDnfg6 ?? Press Release?: https://lnkd.in/eq-cAQKF ? #Parkinsons #ClinicalTrials #Biopharmaceuticals #Innovation #DrugDevelopment #Serotonin

???? ???????????????? ???? ?????????? ???????? ???????????????? ??????. Rare diseases affect over 300 million people worldwide: ???????? ???????????????????? ???????????????????? –?Over 6,000 distinct rare diseases have been identified –?5 % of the world’s population is affected at some point in life ?????????? ???????????????? ???????????? –?Over $800 billion annually in the United States alone. –?Burden per-patient is 10-fold greater than for more common diseases ???????????????????????? ?????????????????? ???????????????????????? –?Fewer than 10% of rare diseases have approved treatments –?Standard of care is often limited to management of symptoms On Rare Disease Day 2025, Neurolixis is proud of its cutting-edge research aimed at addressing the unmet medical needs of patients suffering from three debilitating rare neurological diseases. The company's first-in-class drug candidates target the serotonin system to alleviate symptoms, have neuroplastogenic properties and show disease-modifying activity: NLX-112 (Phase 2) for ?????????????????????????????? ????????????, NLX-101 (Phase 1) for ?????????????? ?? ???????????????? and ???????? ????????????????. ? ?? Information on Rare Disease Day:?https://lnkd.in/gk6hbAF ?? 3-minute video summary of the Neurolixis rare disease programs:?https://t.ly/SNq4H ?? Full Press Release?: https://lnkd.in/ePCnbpZH ?? Pharmacology review of Neurolixis serotonin 'biased agonists':?https://t.ly/hCB8y #ataxia #rettsyndrome #fragileX #drugdevelopment

???????????????????? is making strides in developing first-in-class treatments for rare neurological disorders. Our lead drug candidate,???????-??????, is Phase 2-ready and has received Orphan Drug designation for treating ?????????????????????????????? ????????????. With a proven safety record in over 600 subjects and beneficial motor effects in people with Parkinson’s disease, NLX-112 could be a breakthrough in the movement disorders field. Additionally,???????-???????(Phase 1) has Orphan Drug designation for treating Autism Spectrum Disorders: ?????????????? ?? ???????????????? ?????? ???????? ????????????????, two debilitating neurodevelopmental conditions with high medical need. Both NLX-112 and NLX-101 have neuroprotective and neuroplastogenic effects, suggesting ??????????????-?????????????????? ?????????????????????? ????????????????. Neurolixis CEO, Adrian Newman-Tancredi, recently presented our rare disease pipeline at the ???????? ???????????? ?????????? ?????????????????? ????????????????????. ?? See the 3-minute Neurolixis Roundtable presentation: https://lnkd.in/eAXayE5d ? #RareDiseases #DrugDevelopment #Ataxia #FragileX #RettSyndrome #OrphanDrug

?? ?????????? ?????????? ???? ???????? ???????Neurolixis! New research further supports development of ??????-??????, a serotonin 5-HT1A receptor biased agonist, for treatment of rare ???????????? ???????????????? ??????????????????. The results from Khaleel Abdulrazak and Xin Tao at the University of California, Riverside, showed that NLX-101 improves EEG signals in transgenic ?????????????? ?? ???????????????? mice. NLX-101 holds ???????????? ???????? ???????????? for treatment of both ?????????????? ?? ???????????????? and ???????? ????????????????, another rare autism spectrum disorder. Full publication (open access): https://lnkd.in/eB5rPpQ7 #FragileX #serotonin #autism #drugdevelopment #research

???????????????????? ?????????????? ???????????? ?????????????????? ?????????????? ?????????????????????? ???? ?????? ???? ?????? ??????-?????? ???? ?? ???????????????????????????? ?????????????????? ?????? ?????????????????????????????? ???????????? ? The ???????????????? ???????????????????? has granted Orphan Medicinal Product (OMP) designation to Neurolixis for ??????-?????? (??????????????????),?a selective serotonin 5-HT1A receptor full agonist, for the treatment of ?????????????????????????????? ???????????? (??????). ? SCA is a group of rare genetic disorders, most notably ??????????????-???????????? ?????????????? (????????),?which leads to progressively worsening neurological symptoms such as clumsiness, muscle weakness, and tremors, often resulting in severe disability. The OMP designation for NLX-112 was awarded following a successful collaboration between Neurolixis and Professor Patricia Maciel's team at the University of Minho in Portugal. This partnership, funded by the ??.??. ???????????????????? ???? ??????????????, showed that NLX-112 significantly reduces motor dysfunction in a transgenic mouse model of SCA3. ? ?? Full Press Release: https://t.ly/hUL6R ?? European Medicines Agency Announcement: https://t.ly/qkjCd ?? More on Spinocerebellar Ataxias: https://t.ly/UoIFL ?? Info on NLX-112 and Related Compounds: https://t.ly/hCB8y ? #movementdisorder #serotonin #drugdevelopment #pharmaceutical #raredisease #orphandrug #machadojoseph

???????????????????? ?????????? ???????? ???????? ?????????? ???????????????????????????? ?????? ???????????????????????????? ???????????????????? ???? ??????-??????, ?? ??????????-????-?????????? ??-???????? ???????????????? ???????????? ??????????????. In a collaboration with the team of Paul Albert, at the University of Ottawa, Canada, NLX-101 exhibited rapid-acting and robust antidepressant activity in mice that are genetically resistant to classical antidepressants such as fluoxetine (Prozac ?). Moreover, NLX-101 also induced widespread increases in the density of 5-HT neuron projections, including axons and synaptic structures, consistent with a neuroplastic rescue of serotonergic signaling. These data further support the ongoing development of NLX-101 for treatment of mood disorders and autism spectrum disorders. Full article (open access): https://t.ly/qmpKX

A great example of an effective and patient-centered collaboration between FRAXA Research Foundation, University of California, Riverside and Neurolixis: the ground-breaking research on the first-in-class 5-HT1A receptor biased agonist, ??????-??????, is accelerating its development as a treatment for Fragile X syndrome. #serotonin #drugdevelopment #autism

???????????????????? ?????????????? ?????? ???????? ???????????? ???????????????? ?????????????????? ?????????????? ???????? ?? ?????? ???? ???????????? ?????? ?????????????????? ???? ?????????????? ?? ????????????????. The USPTO granted Neurolixis a patent protecting the use of NLX-101, a first-in-kind, selective serotonin 5-HT1A receptor biased agonist, for treatment of Fragile X syndrome, a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved treatments for Fragile X syndrome, and, in a transgenic mouse model, NLX-101 robustly attenuates the sensory hypersensitivity which is associated with anxiety and stress in people with FXS. Full Press Release: https://lnkd.in/eHMwMN3E For more information on Fragile X syndrome: FRAXA Research Foundation For information on NLX-101 in a model of FXS : https://t.ly/ETadg To view the patent: https://t.ly/cda6o For a review of Neurolixis 5-HT1A receptor biased agonists: https://t.ly/hCB8y #autism #fragileXsyndrome?#drugdevelopment?#serotonin?#pharmaceutical??

??????????????????'?? ?????????????? (????) ???? ?????? ???????????? ???????? ???????????? ?????????????????????????????????? ?????????????????? ?????????? ??????????????????'??, with over 8 million people worldwide living with the disease. In the US, as many as 1 million people live with PD and nearly 90,000 people are diagnosed with PD each year. Economic costs exceed $50 billion in the US alone and there is a pressing need for safe and well tolerated new treatments. Neurolixis is developing ??????-??????, ?? ??????????-????-???????? ??????-???????????????????????? ?????????????????? ?????? ????????????????????, a troubling disorder that affects many people with PD after 5 to 10 years. Unlike existing drugs, NLX-112 targets the serotonin system in the brain. Find out more: https://t.ly/Uy1_6 and https://t.ly/3ekaa #Parkinson #Serotonin #Drugdevelopment